MyPath: Developing and implementing innovative Patient-Centred Care Pathways for cancer patients

在欧盟，2020年有270万人被诊断患有癌症，130万人死于癌症。由于早期检测和新疗法的进步，超过1200万人从癌症中幸存下来。随着治愈率的提高和癌症患者寿命的延长，获得以患者为中心的护理，包括最佳支持、姑息治疗、生存和临终关怀，变得越来越重要。然而，癌症护理仍然存在孤岛，直到今天，还没有适合不同文化、环境和环境的技术支持。一些随机对照试验提供了证据，证明在标准肿瘤治疗中整合以患者为中心的护理可以改善患者和护理人员的预后。到目前为止，这些发现还没有转化为临床常规。在这个项目中，我们将开发技术增强和基于证据的以患者为中心的护理途径，称为MyPath，将其与以肿瘤为中心的治疗相结合，包括支持性治疗、姑息治疗、生存治疗和临终关怀。MyPath整合了OUSEir软件的患者报告结果，并在欧洲著名肿瘤学家、伦理学家、心理学家和社会学家的贡献下进一步发展。它将在我们的中小企业合作伙伴DNV Imatis的电子健康平台上配置。其有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会sesmo和EAPC以及癌症患者组织ECPC的支持下，我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和可及性，减少临床实践中的变化，并优化家庭、社区和医院护理环境中的资源。这将最终减少与癌症相关的身体、情感和经济负担

In the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanksto advancesin early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred careconsisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer carestill has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments.Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology careresults in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we willdevelop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centredtreatments across supportive, palliative, survivorship and end-of-life care. MyPath integrates patient-reported outcomes of the OUSEir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. Itwill be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed inan implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associationsESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at theright time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care,reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reducethe physical, emotional, and ultimately economic burden linked to cancer